Trichomonas vaginalis Antibody (7121): sc-58206

Trichomonas vaginalis Antibody (7121) is a mouse monoclonal IgG1 antibody that detects Trichomonas vaginalis in Trichomonas vaginalis by immunofluorescence (IF). Trichomonas vaginalis is an anaerobic parasite responsible for trichomoniasis, the most prevalent pathogenic protozoan infection in humans, which affects the genitourinary tract. This organism is notable for its unique energy metabolism; lacking mitochondria, it relies on glycolysis and a specialized organelle known as the hydrogenosome to convert pyruvate and malate into hydrogen and acetate, thus fulfilling its energy requirements. The hydrogenosome plays a crucial role in the parasite′s survival, allowing it to thrive in anaerobic environments and capture nutrients through phagocytosis. Trichomonas vaginalis is remarkably resilient, capable of persisting for up to 24 hours in various fluids such as urine, semen, and even water, which underscores its potential for transmission and infection. Anti-Trichomonas vaginalis antibody (7121) is an essential tool for researchers studying this parasite′s biology and pathogenesis, providing insights into its unique metabolic pathways and interactions within the host.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Trichomonas vaginalis Antibody (7121) References:

1. APTIMA® Trichomonas vaginalis, a transcription-mediated amplification assay for detection of Trichomonas vaginalis in urogenital specimens.  |  Chapin, K. and Andrea, S. 2011. Expert Rev Mol Diagn. 11: 679-88. PMID: 21902528
2. Basic biology of Trichomonas vaginalis: current explorations and future directions.  |  Land, KM. and Wrischnik, LA. 2013. Sex Transm Infect. 89: 416-7. PMID: 23956295
3. Biological roles of cysteine proteinases in the pathogenesis of Trichomonas vaginalis.  |  Hernández, HM., et al. 2014. Parasite. 21: 54. PMID: 25348828
4. Polyamine Transport and Synthesis in Trichomonas vaginalis: Potential Therapeutic Targets.  |  Alvarez-Sanchez, ME., et al. 2017. Curr Pharm Des. 23: 3359-3366. PMID: 28671057
5. Comparison of Two PCR Assays for Trichomonas vaginalis.  |  Noh, CS., et al. 2019. Korean J Parasitol. 57: 27-31. PMID: 30840796
6. Neonatal pneumonia caused by Trichomonas vaginalis.  |  Pokrývková, M., et al. 2020. Epidemiol Mikrobiol Imunol. 69: 96-99. PMID: 32819109
7. Investigating links between Trichomonas vaginalis, T. vaginalis virus, Mycoplasma hominis, and metronidazole resistance.  |  Govender, R., et al. 2024. J Infect Dev Ctries. 18: 1590-1600. PMID: 39616490
8. Pathogenicity of Trichomonas vaginalis.  |  Graves, A. and Gardner, WA. 1993. Clin Obstet Gynecol. 36: 145-52. PMID: 8435939
9. Trichomonas vaginalis adhesin proteins display molecular mimicry to metabolic enzymes.  |  Engbring, JA., et al. 1996. Adv Exp Med Biol. 408: 207-23. PMID: 8895795
10. Clinical and microbiological aspects of Trichomonas vaginalis.  |  Petrin, D., et al. 1998. Clin Microbiol Rev. 11: 300-17. PMID: 9564565